Home › Momenta Pharmaceuticals Announces Publication Revealing Development Of A Novel Process To Generate High-Quality Hyper-Sialylated IVIg Drug Candidate In PNAS
 

Keywords :   


Momenta Pharmaceuticals Announces Publication Revealing Development Of A Novel Process To Generate High-Quality Hyper-Sialylated IVIg Drug Candidate In PNAS

2015-03-04 05:59:44| drugdiscoveryonline Home Page

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that results from preclinical studies on its hyper-sialylated IVIg (hsIVIg) program were published in this week's Early Edition of Proceedings of the National Academy of Sciences (PNAS)

Tags: development process publication drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 7
05.11Tropical Storm Rafael Public Advisory Number 7
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 7
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
More »